Target intelligence / Profile preview

SH3 and multiple ankyrin repeat domains protein 3 (SHANK3)

Target
SHANK3
Molecular classification
Scaffold protein, Postsynaptic density protein, Structural protein, Signaling protein (regulates G-protein signaling and actin dynamics), Other (multidomain synaptic protein)
01

Overview

SHANK3, or SH3 and multiple ankyrin repeat domains protein 3, is a major postsynaptic density scaffold protein central to excitatory synapse organization, dendritic spine formation, and synaptic signaling. The protein contains multiple interaction domains (ANK, SH3, PDZ, PRO, SAM), enabling it to connect neurotransmitter receptors, ion channels, and membrane proteins with the actin cytoskeleton and G-protein signaling pathways. Its genetic deficiency or mutation causes autism spectrum disorders and is associated with Phelan–McDermid syndrome due to deletions at chromosome 22q13.3. SHANK3 also plays roles outside the brain, with emerging evidence of involvement in cardiac muscle and possibly other tissues, mediated by its interactions with actin-regulatory proteins and phospholipase Cβ1b. No current therapeutics directly target SHANK3, but it is a key research focus for neuropsychiatric and developmental disorders.

Other names
Proline-rich synapse-associated protein 2 (ProSAP2)Shank3 proteinSH3 and multiple ankyrin repeat domains 3
02

Mechanism of action

Inhibition of integrin activation via sequestration of active Rap1 and R-Ras, antagonizing the Rap1–RIAM–talin pathway. Regulation of synaptic plasticity via scaffolding and organization of postsynaptic complexes Control of actin cytoskeleton dynamics

03

Biological functions

Synaptic formation and maturationDendritic spine growthSynapse development and plasticityRegulation of integrin activationOrganization of macromolecular complexes at synapsesRegulation of actin cytoskeletonModulation of Ras/Rap1 G-protein signalingIn stem cells: regulation of self-renewal, proliferation, differentiation, apoptosis, metabolism
04

Disease associations

Neurodevelopmental disorders (autism spectrum disorder, Phelan–McDermid syndrome/22q13.3 deletion syndrome, intellectual disability)SchizophreniaCardiac dysfunction (suggestive evidence in animal models and heart tissue interactions)Other neurological and psychiatric diseases
05

Safety considerations

Gene dosage sensitivity: haploinsufficiency or mutation is strongly disease-associated (risk of developmental delay, intellectual disability, neurological deficit)Therapeutic challenges include tissue-specific expression, isoform complexity, and potential off-target effects in cardiac or other non-neuronal tissues
06

Interacting drugs

No known approved drugs directly targeting SHANK3 at present, but it is a therapeutic/research target for neurodevelopmental disorder interventions. There may be ongoing preclinical or experimental efforts.
07

Biomarkers

SHANK3 deletion or mutation (for patient selection in autism spectrum disorder and Phelan–McDermid syndrome)Expression levels may serve as efficacy markers for certain experimental therapies

Beyond the preview

Go deeper on SH3 and multiple ankyrin repeat domains protein 3 (SHANK3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SH3 and multiple ankyrin repeat domains protein 3 (SHANK3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call